drugset
drugset / Trial / NCT00730990

A Phase I, Healthy Volunteer Positron Emission Tomography Study

NCT00730990 ↗

Phase 1 Completed 10 enrolled Pfizer Yale University · collab
RandomizedSingle-groupSingle-blindOther

Summary

The primary purpose of this study is to assess central receptor occupancy of PF 03654746 at the H3 receptor after a single oral dose of PF 03654746.

Timeline

Start
2008-05
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03654746 Small molecule 0.5 mg Oral
Subject PF-03654746 Small molecule 1.5 mg Oral
Subject PF-03654746 Small molecule 4 mg Oral

Indications

No indication recorded.